Japan approves medical insurance coverage for iPS cell-derived cardiac muscle therapy

Japanese regulators have authorized national health insurance coverage for cardiac muscle sheets derived from induced pluripotent stem (iPS) cells. This marks a significant regulatory milestone for regenerative medicine in treating severe heart failure, though long-term clinical efficacy and scalability remain to be proven.